Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Zydus Lifesciences Ltd is an India-based life sciences company. The Company has a pipeline for Biologics and Vaccines.
Customise key metrics, see detailed forecasts, download stock data and more
Pledged promoter holdings is insignificant
In last 3 months, mutual fund holding of the company has almost stayed constant
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 24, 2024, titled "Zydus Lifesciences announces completion of Enrolment for Phase II clinical trial of Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)." | Download
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 24, 2024, titled "Zydus Lifesciences announces completion of Enrolment for Phase II clinical trial of Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)." | Download
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 22, 2024, titled "Zydus receives final approval from USFDA for Theophylline Extended-Release Tablets, 300 mg and 450 mg". | Download
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 22, 2024, titled "Zydus receives final approval from USFDA for Theophylline Extended-Release Tablets, 300 mg and 450 mg". | Download
Final • Div/Share: ₹ 6
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant